• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Horizon Discovery, AstraZeneca collaborate on oncology drug discovery

Horizon Discovery, AstraZeneca collaborate on oncology drug discovery

April 22, 2013
CenterWatch Staff

Horizon Discovery, a provider of research tools to support translational genomics research, and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon's first-in-class kinase target program, HD-001, as a means of developing novel therapies for multiple cancer types.

Horizon will receive undisclosed upfront and preclinical milestone payments, and are eligible for clinical and approval milestones totaling up to $75 million, as well as tiered royalties.

The HD-001 program, currently in the early stages of drug discovery, has the potential to be developed into a treatment based on modulation of a novel kinase. This target has been shown to be mutated in a range of cancer types including colon and lung. The target has also been shown to play a key role in K-Ras mutant tumors. K-Ras is mutated in up to 40% of all cancer types causing resistance to many of the available targeted therapeutics and as a result is associated with poor patient outcomes, which makes the development of molecular targeted therapies against the gene a significant unmet need.

"Targeting cancer cells harboring mutant K-Ras has been a perennial issue for the drug discovery community, with few canonical pathway or 'gene-addiction' targets showing a clear benefit on this important cancer gene,” said Dr. Chris Torrance, CSO and leader of the HD-001 program, Horizon. “We are excited to partner with Astra Zeneca on the development of HD-001, as they have shown a firm commitment to the identification of novel K-Ras targets."  

Susan Galbraith, head of the oncology innovative medicines unit, AstraZeneca, said, "Horizon's novel kinase target program coupled with their target validation technology allows us to broaden our oncology research efforts beyond our own internal capabilities. AstraZeneca has a proven track record of collaborating on early stage discovery projects with innovative organizations like Horizon, partnering their cutting-edge science with our strong oncology expertise to bring new medicines to cancer patients."

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing